Psyence Group (EKW0) Stock Overview

A life science biotechnology company, engages in the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma. More details

EKW0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap (€2M)

Shareholders have been substantially diluted in the past year

Earnings have declined by 11.5% per year over past 5 years

+ 2 more risks

EKW0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

776

US$21.53

72.3% undervalued

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Psyence Group Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Psyence Group
Historical stock prices
Current Share Price	CA$0.064
52 Week High	CA$0.13
52 Week Low	CA$0.058
Beta	1.24
1 Month Change	0%
3 Month Change	-0.78%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-20.99%

Recent updates

Shareholder Returns

	EKW0	DE Biotechs	DE Market
7D	0%	0.7%	-1.2%
1Y	n/a	-8.6%	7.1%

Return vs Industry: Insufficient data to determine how EKW0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how EKW0 performed against the German Market.

Price Volatility

Is EKW0's price volatile compared to industry and market?
EKW0 volatility
EKW0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.9%
Market Average Movement	5.2%
10% most volatile stocks in DE Market	13.1%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: EKW0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine EKW0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2019	n/a	n/a	psyence.com

Psyence Group Inc., a life science biotechnology company, engages in the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma. It operates in two segments, Clinical Trial Activities and Non-Clinical Trial Activities. The company develops botanical psilocybin-based psychedelic medicine, which works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Psyence Group Inc. Fundamentals Summary

How do Psyence Group's earnings and revenue compare to its market cap?
EKW0 fundamental statistics
Market cap	€1.16m
Earnings (TTM)	-€7.62m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is EKW0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EKW0 income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$12.30m
Earnings	-CA$12.30m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.79
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did EKW0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/02/01 02:31
End of Day Share Price	2025/11/24 00:00
Earnings	2025/09/30
Annual Earnings	2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Psyence Group Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ryan Hampton	Hannam & Partners (Advisory) LLP

Psyence Group Inc.DB:EKW0 Stock Report